Mylanta Max Strength Classic Flvr 12 Floz Distributed To Specific Family Dollar shortage — US supply status & alternatives

Mylanta Max Strength Classic Flvr 12 Floz Distributed To Specific Family Dollar

—

In supply · Australia

Mylanta Max Strength Classic Flvr

In supply · 🇦🇺 Australia · short in🇨🇦 CA🇺🇸 US

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Mylanta Max Strength Classic Flvr 12 Floz Distributed To Specific Family Dollar
Brand names	Mylanta Max Strength Classic Flvr
Therapeutic category	Auto-created by FDA MedWatch — Drug Safety Alerts scraper
Controlled substance	No
Patient information leaflet (PIL)	Not on file
Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Recalls official enforcement reports

🇨🇦

Mylan product recalls (2015

Drugs and health products · Mar 2015

Class Idetails ↗

🇨🇦

Mylan Recalls Methotrexate Injection (USP 50mg/2mL) Due To Particulate Matter

Communications and Public Affairs Branch · Mar 2015

Class ?details ↗

🇨🇦

Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump

Communications and Public Affairs Branch · Sept 2014

Class ?details ↗

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.